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ImmunohistochemistryAbstract Background: O6-methylguanine-DNA methyltransferase (MGMT) protein expression
using immunohistochemical analysis was proposed as a prognostic marker for patients with newly
diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant
Temozolomide (TMZ).
Methods: From April 2012 to October 2014, 73 patients with newly diagnosed GBM, MGMT
protein expression were analyzed in formalin-fixed, paraffin-embedded tumor specimens. Patients
received the radiation therapy plus concomitant and adjuvant TMZ chemotherapy.
Results: For the whole cohort, the median overall survival (OS) was 15 months, and the
progression-free survival was 10 months. Patients who had low MGMT protein expression
(615%) had a significantly improved OS and PFS compared with patients who had high MGMT
expression (17.0 months vs 14 months; P value .006) and (15.0 months vs 10 months; P value .016)
respectively. The age and extent of tumor resection were the strongest clinical predictors of out-
come. In multivariate Cox models MGMT protein expression, extent of tumor resection and age
were identified as independent prognostic factors.7939561.
24 S.G. Younis et al.Conclusions: MGMT expression was identified as positive prognostic factor in patients with newly
diagnosed glioblastoma who underwent surgical resection followed by adjuvant radiotherapy and
concomitant oral TMZ chemotherapy (the Stupp protocol).
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Aim of this work: Assessment of prognostic value of
O6-methylguanine-DNA methyltransferase (MGMT) protein
expression using immunohistochemical analysis for patients
with newly diagnosed glioblastoma (GBM) treated with radia-
tion therapy with concurrent and adjuvant Temozolomide.
Introduction
Glioblastoma (GBM) is the most common primary malignant
brain tumor in adults [1]. The worldwide incidence rate of
primary malignant brain and CNS tumors in 2012, was 3.4
per 100,000. Incidence according to gender was 3.9 per
100,000 in males and 3.0 per 100,000 in females. This
represented an estimated 139,608 males and 116,605 females
who were diagnosed worldwide with a primary malignant
brain tumor in 2012, an overall total of 256,213 individuals.
The incidence rates were higher in more developed countries
(5.1 per 100,000) than in less developed countries (3.0 per
100,000) [2].
In spite of multimodal intensive treatments including max-
imum surgical resection followed by radiation therapy and
chemotherapy the median overall survival (MS) of patients
with GBM remains 12–15 months from the time of initial diag-
nosis [3].
Temozolomide (TMZ) is an alkylating agent that is rapidly
absorbed after oral administration, and penetrates well into
the cerebrospinal fluid at a concentration up to 40% of that
measured in plasma [4]. TMZ has been shown to have clinical
antitumor activity against malignant gliomas and a relatively
good safety profile [5].
The European Organization for Research and Treatment of
Cancer (EORTC) and the National Cancer Institute of
Canada (NCIC) conducted a trial ‘‘referred to Stupp protocol”
demonstrated that concomitant radiotherapy (RT) plus TMZ
followed by six cycles of TMZ, significantly improved the med-
ian survival compared with RT alone in patients with newly
diagnosed GBM. The RT plus concomitant and adjuvant
TMZ regimen has thus been considered as the standard of care
for these patients [6].
O6-methylguanine-DNA methyltransferase (MGMT) is a
key enzyme in the base-excision pathway of DNA repair
(BER). MGMT removes mutagenic and cytotoxic adducts
from O6-guanine in DNA, the preferred point of attack for
alkylating drugs, such as Temozolomide (TMZ), which is used
in the treatment of glioblastoma [7].
The mechanism of action by TMZ is thought to be methy-
lation at the O6 position of guanine in DNA, with additional
methylation at the N7 position [8,9]. These alkylating injuries
are effectively repaired by a DNA repair enzyme O6-
methylguanine-DNA methyltransferase. MGMT catalyzes
the stoichiometric, covalent transfer of the alkyl group to an
internal cysteine residue, and is finally inactivated [10].A significant correlation was found between MGMT pro-
tein expression determined by immunohistochemistry (IHC)
and survival of patients with newly diagnosed GBM treated
with RT plus concomitant and adjuvant TMZ [11,12]. The
methylation of the promoter region of MGMT gene has been
shown to be a major mechanism to turn off gene transcription,
thus it may reduce the intracellular level of MGMT expression
[13].
High levels of MGMT activity in tumor tissue are associ-
ated with resistance to alkylating agents [5]. In contrast, epige-
netic silencing of the MGMT gene by promoter methylation
results in decreased MGMT expression in tumor cells [9,10].
At least 3 methods are available for evaluating MGMT sta-
tus: such as determining MGMT enzyme activity by using
snap-frozen tumor samples, which may limit routine use, eval-
uating MGMT protein expression by immunohistochemistry
(IHC) using paraffin-embedded tumor tissues, and establishing
MGMT promoter methylation status based on methylation-
specific polymerase chain reaction (MSP) or pyrosequencing
[14]. Because contradictory results have been reported across
laboratories based on these methods, agreement on the best
and most reliable technique for evaluating MGMT status still
needs to be achieved [15,16].
Materials and methods
Patient eligibility criteria
Between April 2012 and October 2014, 73 patients with a
newly diagnosed pathologically proven, GBM (WHO grade
4 astrocytoma), in Clinical Oncology Department, Tanta
University Hospital and Tanta Cancer Center were enrolled.
Patients were followed up until July 2015. At the time of
analysis, the median follow up duration was 13 months
(Range; 9–27 months).
Patients fulfilled the following criteria: age older than
18 years, Karnofsky performance status (KPS) of P60, ade-
quate bone marrow reserve (WBC count P3.5  109/L,
ANC countP1.5  109/L, plateletsP100  109/L, and hemo-
globin P9 g/dL), adequate renal function (measured
creatinine clearance level P60 mL/min, serum creatinine
61.7 mg/dl and blood urea 625 mg/dl) and adequate liver
function (transaminases less than 3  upper normal limit,
and serum bilirubin level allowed below 1.5 mg/dL).
Patients were ineligible for this study if they had metastases
to distant sites, or were pregnant or had dementia, altered
mental status, or any psychiatric condition that would prohibit
the understanding or rendering of informed consent. Also,
patients suffering from secondary malignancy or concurrent
serious, uncontrolled medical illness (e.g. persistent immune-
compromised states, uncontrolled infection, and clinically
significant cardiac disease) were not eligible.
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University, granted protocol approval and all patients signed
an informed consent before the initiation of any treatment.
Study design and treatment protocol
After initial diagnosis of glioblastoma multiforme, we assigned
eligible patients for concurrent Temozolomide with radiation
started 2–4 weeks post-surgery and paraffin blocks were col-
lected for MGMT protein expression analysis, then we further
grouped patients to either low (615% positively stained
nuclei) or high (>15% positively stained nuclei) protein
expression (17–18), after concurrent chemo radiation for four
weeks patients started adjuvant Temozolomide as detailed
below.
Surgery
All patients underwent surgery with submission of a tumor tis-
sue block with a minimum of 1 cm2 of tumor for immunohisto-
chemical analysis. The extent of surgical excision was defined
according to post-operative magnetic resonance imaging
(MRI) or computed tomography (CT) as total resection is com-
plete disappearance of contrast enhancement, subtotal resection
is disappearance of P90% of contrast enhancement, partial
resection is disappearance of <90% of contrast enhancement.
Chemotherapy
Temozolomide at a dose of 75 mg/m2; 7 days per week over a
40 day period with maximum 49 doses, was started along with
the radiotherapy and was continued on a daily basis until com-
pletion of radiation treatment. During the concomitant radio-
therapy and Temozolomide treatment antiemetic prophylaxis
was recommended before initiation of treatment.
Adjuvant Temozolomide treatment was initiated 4 weeks
after completion of radiotherapy. Patients received Temozolo-
mide at a dose of 175 mg/m2 for 5 consecutive days of a 28 day
cycle, Treatment was planned for six cycles.
Radiotherapy
Radiotherapy consisted of fractionated, conformal radiation
given at a daily dose of 2 Gy. Treatment was delivered 5 days
a week for a total of 6 weeks to a total dose of 60 Gy. The
radiotherapy protocol allowed consisted of: an initial volume
consisting of enhancement, postoperative cavity, plus sur-
rounding edema (or fluid-attenuated inversion recovery
[FLAIR] abnormality defined by magnetic resonance imaging
[MRI]) and a 2 cm margin received 46 Gy in 23 fractions fol-
lowed by a boost of 14 Gy in seven fractions to the area of
enhancement plus the cavity and a 2.5 cm safety margin.
Paraffin blocks collection
Paraffin blocks of the eligible patients were retrieved from the
archives of Pathology Department, Faculty of Medicine,
Tanta University and Tanta Cancer Center. Hematoxylin
and eosin (H and E) sections were prepared from all blocks.
Informed consents for the investigational research using thepatient’s paraffin blocks were fully obtained from all patients
included in the study.
Immunohistochemistry
Five micrometer thick sections of 10% formalin-fixed,
paraffin-embedded (FFPE) tissues were immuno-stained for
O6-methylguanine-DNA methyltransferase (MGMT). The
primary antibody was supplied by Santa Cruz Biotechnology.
Sections were deparaffinized in xylene and treated with 0.3%
hydrogen peroxide in methanol for 20 min to block endoge-
nous peroxidase activity. The sections were washed in phos-
phate buffered saline and then incubated with primary
antibody (dilution 1:50) over night. The slides were then incu-
bated in secondary antibody. The substrate chromogen, 3.30-
diaminobenzidine (DAB), enabled visualization of the nuclear
expression of MGMT via a brown precipitate. Hematoxylin
(blue) counterstaining enabled the visualization of the cell
nuclei. Omission of primary antibody served as a negative con-
trol. Staining of endothelial cells was used as positive internal
control.
At least 100 cells were evaluated for nuclear MGMT stain-
ing. We chose areas with prominent signs of anaplasia, espe-
cially areas of high cellularity and nuclear polymorphism.
Endothelial cells and perivascular lymphocytes were omitted
from analysis.
According to Capper et al. and Lechapt-Zalcman et al. who
found that the best cut off value of MGMT protein expression
was 15%; we divided our studied cases into low expression
group (615%) positively stained nuclei which was considered
immunonegative and high expression group (>15%) posi-
tively stained nuclei which was considered immunopositive
[17,18].
Statistical analysis
SPSS 21.0 software version (SPSS, Inc.) was used for data
analysis. To identify any selection bias when grouping patients
according to MGMT protein expression, baseline characteris-
tics of the 2 patient groups were compared using chi-square/
Fischer exact tests. Overall-survival (OS) rates were calculated
from the time of initial treatment (date of surgery) to the time
of the last follow-up visit or death. Progression-free survival
(PFS) was the time elapsed from the date of initiation of treat-
ment to the date of first evidence of disease progression or
death in the absence of disease progression. Kaplan–Meier
method was used for estimating survival and log rank was used
to compare between the different prognostic factors. Mean and
standard deviation were used to estimate the quantitative data.
Stepwise multiple regression analyses were performed using a
Cox proportional hazards model, estimating the adjusted haz-
ard ratio (HR) with 95% confidence intervals (CI) for age, sex,
KPS, extent of tumor resection and MGMT protein expression
relative to the risk of death or disease progression. Statistical
tests used were two sided and the significance was considered
at values of P 6 0.05.
Results
This study was conducted between April 2012 and October
2014 and recruited a total of 73 patients, including 31 females
26 S.G. Younis et al.and 42 males, who had a median follow-up of 13 months
(range, 9–27 months).
Patient characteristics in relation to MGMT protein expres-
sion are summarized in Table 1. The mean age was 55.8 years
(range, 27–76 years), and the mean KPS score was 83.4 ± SD
12.5. Patients’ clinical features and tumor immunohistochemi-
cal profiles were compared (Table 1).
Progression-free survival
The median PFS was 10 months (95% CI, 7.5–12.5 months)
for the whole patient series, and the PFS rate was 100%,
41% and 15.4% at 6 months, 12 months and 18 months
respectively.Figure 1 Kaplan–Meier estimates of progression-free
Table 1 Clinicopathological features of glioblastoma multi
radiation (n= 73).
Characteristics MGMT protein expression n of patients
Low expression or immunonegative 615%
n= 38 %
Age (years)
650 21 52.5
>50 17 51.5
Sex
Female 15 48.4
Male 23 54.8
KPS
P80 32 51.6
<80 6 54.5
Extent of resection
Total excision 9 50.0
Subtotal and Partial 19 52.8
Biopsy 10 52.6
n, number of patients.
KPS, Karnofsky performance score.
P value 60.05 considered significant.In univariate analysis age, MGMT protein expression and
extent of tumor excision were the only clinical factors that
influenced PFS: The median PFS for patients 650 years
was14 months versus 9 months for those older than 50 years
(P= 0.01) whereas PFS was significantly longer for patients
with low MGMT protein expression (15 months vs 10 months)
than those with high MGMT protein expression; (P value
0.016) (Fig. 1),whereas patients operated by total excision
had longer PFS than those with biopsy only (16 m vs 8.5 m).
Other factors, such as sex and KPS did not significantly influ-
ence PFS in univariate analysis (Table 2).
In the multivariate stepwise Cox proportional hazards
model, revealed that patients who had high MGMT protein
expression had about 2 times risk of disease progressionsurvival according to MGMT protein expression.
forme patients treated with Temozolomide-based chemo
73 P-value*
High expression or immunopositive >15%
n= 35 %
19 47.5 0.933
16 48.5
16 51.6 0.590
19 45.2
30 48.4 0.858
5 45.5
9 50.0 0.980
17 47.2
9 47.4
Table 2 Association between clinical features or status of MGMT protein expression and progression free survival, assessed by
univariate analysis (log rank test).
Factors Total number Number progressed 1 year PFS (%) Median 95% CI (m) P-value
Total 73 57 41.0 10 (7.5–12.5)
Age (years) 650 40 25 56.4 14 (9.1–18.9)
>50 33 32 34.3 9 (8.6–9.4) 0.010
Sex Male 42 32 41.3 10 (8.7–11.3)
Female 31 25 40.7 11 (8–14) 0.671
KPS P80 62 48 44.8 12 (9–15)
<80 11 9 13.9 9 (8–10) 0.239
Surgery Total excision 18 13 61.1 16 (9.3–22.7)
Subtotal and partial 36 29 43.2 11 (8.6–13.4)
Biopsy 19 15 15.8 8.5 (7.9–9.1) 0.013
MGMT Ptn expression 615 38 28 59.8 15 (12–18)
>15 35 29 21.6 10 (9.4–10.6) 0.016
Median survival and 95% confidence interval, in months.
KPS, Karnofsky performance status.
Ptn, protein.
Table 3 Multivariate stepwise Cox proportional hazards
analysis for factors associated with progression.
95.0% CI for HR
HR Lower Upper P-value
Age 2.18 1.26 3.77 0.006
Surgery 0.008
Total vs subtotal 1.35 0.68 2.66 0.388
Total vs biopsy 3.33 1.48 7.45 0.004
MGMT expression 1.98 1.13 3.46 0.017
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(HR, 1.98; 95% CI, 1.13–3.46; P value 0.017) (Table 3).
Overall survival
The median OS was 15 months (95% CI, 12.8–17.2 months)
for the overall study population, with OS rates of 100, 63%,
32.3% and 14.8% at 6, 12, 18 and 24 months, respectively.Figure 2 Kaplan–Meier estimates of over-all surIn univariate analysis, the factors that influenced OS were
MGMT protein expression (17 months vs 14 months; P value
.006) (Fig. 2), age at diagnosis (17 months for 650 years vs
13 months for patients older than 50 years P value .014) and
surgery (18 months for total excision, 16 months for subtotal
and partial excision vs 11 month for biopsy only; P value
.013) (see Fig. 3). Other factors, such as sex and KPS score,
did not significantly influence OS in univariate analysis
(Table 4).
In a multivariate Cox model, patients who had high
MGMT protein expression according to IHC analysis had
2.3 times risk of deaths compared with those who had low
MGMT protein expression (HR, 2.32; 95% CI, 1.3–4.15; P
value .004) (Table 5). At the final analysis in July 2015, 55 of
73 patients (75.3%) had died.
Discussion
GBM is an aggressive disease as no curative therapies are
available, and few well-established prognostic factors havevival according to MGMT protein expression.
Figure 3 Representative photomicrographs of MGMT immunoreactivity. (A) Glioblastoma multiforme showing low MGMT nuclear
expression. (B) Another case showing low expression of MGMT, endothelial staining was used as internal positive control (arrow). (C)
Glioblastoma case with high immune-reactivity for MGMT. (D) Another case showing also high expression for MGMT. Note positive
endothelial cells as positive internal control (arrow) ( 400).
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oncology are directed to developing more efficient therapies,
but only a small percentage of patients experience significant
clinical benefit and prolonged survival [18,19].
In spite of the variability of the clinical responses, the
majority of patients with GBM are presently treated in a uni-
form standardized therapeutic approach, following a principle
‘one fits all’, regardless of the individual molecular characteris-
tics of each tumor that most likely affect patient prognosis.
Consequently, many patients display minor responses and
major therapy-related toxicities [19].Treatment by radiotherapy plus concomitant and adjuvant
TMZ for GBM has led to a small but significant improvement
in patient outcome [6]; however, the responses are still very
poor and unpredictable.
In this study, our objective was to further define the prog-
nostic significance of MGMT protein expression in a series of
patients with newly diagnosed glioblastoma treated according
to the Stupp protocol (concurrent chemoradiation followed by
adjuvant chemotherapy) [6,20]. MGMT expression was inves-
tigated by immunostaining of paraffin sections from tumor
blocks of the studied cases.
Table 5 Multivariate stepwise Cox proportional hazards
analysis for factors associated with survival.
95.0% CI for HR
HR Lower Upper P-value
Age 2.01 1.15 3.48 0.014
Surgery 0.005
Total vs subtotal 1.07 0.54 2.12 0.851
Total vs biopsy 2.92 1.36 6.28 0.006
MGMT expression 2.32 1.30 4.15 0.004
HR, hazard ratio.
CI, confidence interval.
Table 4 Association between clinical features or status of MGMT protein expression and overall survival, assessed by univariate
analysis (log rank test).
Survival (%)
Characteristic Total
number
Number
dead
1 year 2 years Median OS
95% CI (m)
P-value
Total 73 55 63.0 14.8 15 (12.8–17.2)
Age (years) <50 40 26 70.5 19.8 17 (14–20)
P50 33 29 79.1 9.2 13 (11–15) 0.020
Sex Male 42 31 58.3 16.9 14 (11.1–16.9)
Female 31 24 69.9 13.6 15 (11.7–18.3) 0.846
KPS P80 62 47 66.4 14.2 16 (14–18)
<80 11 8 43.6 16.4 12 (10.4–16.3) 0.258
Surgery Total excision 18 14 66.2 22.7 18 (12.3–23.7)
Subtotal and partial
excision
36 25 79.4 18.3 16 (14.5–17.5)
Biopsy 19 16 28.3 0.0 11 (10.5–11.6) 0.013
MGMT Ptn expression 615 38 26 70.2 23.4 17 (13.8–20.2)
>15 35 29 55.1 4.3 14 (10.6–17.4) 0.006
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reported in previous studies as regards age, sex, performance
status and extent of surgery and, thus, were likely to reflect
daily practice in neuro-oncology. Age at diagnosis is a classic
prognostic factor in glioblastoma series, Our findings are in
agreement with previous studies [6,17].
In current study, the extent of surgery was assessed by
postoperative imaging a significant correlation between the
extent of surgery and both PFS and OS were observed in
our study [6,18].
Our results indicated a median OS (15 months) for the
overall study population compared with the results reported
by Stupp et al. [21] whereas our results were less than that
reported by Lechapt-Zalcman et al. (17.5 months) because of
the use of BCNU wafers during surgery [18]. BCNU wafers
within multimodal treatment strategies may increase survival
with manageable adverse events attributed to slow release of
BCNU from the wafers over 2–3 weeks [18,22,23].
It has been demonstrated that MGMT status is a potent
prognostic factor for patients who receive TMZ concomitant
with and adjuvant to RT and this is in agreement with that
reported by many series [17,18,24,25].
It is well known that methylation specific polymerase chain
reaction (MSP) has been proved to be a sensitive method forassessing MGMT promoter methylation in tumor samples;
which can be done on formalin-fixed, paraffin-embedded
(FFPE) tumor tissues [14]. Lechapt-Zalcman et al. also studied
MSP on FFPE glioblastoma tissue but they recommended
early fixation in buffered formalin to prevent DNA deteriora-
tion. They added that optimal results with MSP need cryopre-
served tumor specimens. However, collecting and preserving
frozen tumor specimens is costly and is not always available
in routine practice [18].
Away from this argument immunohistochemistry presents
several advantages for the detection of MGMT status, pre-
dominantly technical aspects (fast and easy to do, little mate-
rial required, endothelial cells used as internal positive
control, material can be archived in paraffin and antibodies
are commercially available). Therefore, our study, was focused
on MGMT status using immunohistochemical protein
expression.
In our study, low protein expression (<15%) was associ-
ated independently with longer OS and PFS, suggesting the
potential usefulness of this approach in the daily evaluation
of clinical samples, Different cut off values were used in previ-
ous studies, ranging between 5% and 35% [17]. It is notewor-
thy that the value of 15% corresponded to the best cut off
value for identifying better survival rates in glioblastoma
patients [17,18], Capper et al. proposed that cut-off value of
15% lies beyond the observed maximum level of 7% non-
neoplastic nuclear staining cells (i.e., endothelial and inflam-
matory cells) within glioblastomas and they concluded that
these cells can be summed up in the group of low expression
and will not further interfere with the evaluation [17].
Sciuscio et al. performed double immunostaining with non-
tumor cell markers to differentiate glioblastoma cells from
non-neoplastic cells. However, this procedure is costly and dif-
ficult to perform as a routine pathological investigation.
Another explanation for the inconsistent concordance rate
may be related to tumor heterogeneity, a particular feature
of glioblastomas, which often are composed of various clones
of cells within a single tumor [16].
Our study results confirm that MGMT protein expression
is a strong and independent prognostic factor for survival in
30 S.G. Younis et al.patients with glioblastoma, suggesting the potential usefulness
of this approach in the daily evaluation of formalin-fixed,
paraffin embedded samples.
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